FEATURES OF BONE METABOLISM IN PATIENTS WITH DIABETIC OSTEOARTHROPATHY OF VARIOUS STAGES

Kamalov T. T; Tadjibayev S. S.

doi:10.17605/OSF.IO/S7EBN

Authors

Kamalov T. T MD, Head of the Diabetic Foot Department RSNPMTSE them. Y.H. Turakulova
Tadjibayev S. S. Physician - resident of the diabetic foot department RSNPMTSE them. Y.H. Turakulova

DOI:

https://doi.org/10.17605/OSF.IO/S7EBN

Keywords:

type 2 diabetes mellitus , Sharko foot, bone metabolism, markers

Abstract

In this article, the authors studied the features of bone metabolism in 67 patients with type 2 diabetes and with diabetic osteoarthropathy of various stages. The levels of 25-hydroxyvitamin D 3 were significantly lower in patients of all 4 x groups (average age 70 ± 12 years) than in the control group (27.2 ± 6.2 ng / ml).

It should be noted that 34 (50.7%) of patients with diabetic pope ulcers had a severe deficiency of 25-hydroxyvitamin D 3 with levels below 10 ng / ml.

Only 13% of patients, the level of 25-hydroxyvitamin D 3 exceeded 20 ng / ml. In addition, secondary hyperparathyroidism was found in 26% of patients, and at 12.5% of patients a hypocalcemia was revealed.

A negative correlation was established (R = -0.241) (p <00,1) between the classification of Armstrong and the status of 25-hydroxyvitamin D 3.

The authors concluded that patients with diabetic foot syndrome complicated by Stop Charcot are susceptible to high risk of 25-hydroxyvitamin d3 and calcium deficiency. Any patient with the diabetic foot syndrome should take measurement of the level of 25-hydroxyvitamin D 3 and obtain prophylactic treatment when reduced indicators are detected.

Downloads

Download data is not yet available.

References

Vestergaard P., Rejnmark L., Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292–1299. doi: 10.1007/s00125-005-1786-3. [PubMed] [CrossRef] [Google Scholar]

Retzepi M., Donos N. The effect of diabetes mellitus on osseous healing. Clin. Oral Implants Res. 2010;21:673–681. doi: 10.1111/j.1600-0501.2010.01923.x. [PubMed] [CrossRef] [Google Scholar]

Hernandez R.K., Do T.P., Critchlow C.W., Dent R.E., Jick S.S. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop. 2012;83:653–660. doi: 10.3109/17453674.2012.747054. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos. Int. 2007;18:427–444. doi: 10.1007/s00198-006-0253-4. [PubMed] [CrossRef] [Google Scholar]

Picke A.K., Campbell G., Napoli N., Hofbauer L.C., Rauner M. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocrinol. Connect. 2019;8:R55–R70. doi: 10.1530/EC-18-0456. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Lauterbach S., Kostev K., Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J. Wound Care. 2010;19:333–337. doi: 10.12968/jowc.2010.19.8.77711. [PubMed] [CrossRef] [Google Scholar]

Pscherer S., Dippel F.W., Lauterbach S., Kostev K. Amputation rate and risk factors in type 2 patients with diabetic foot syndrome under real-life conditions in Germany. Prim Care Diabetes. 2012;6:241–246. doi: 10.1016/j.pcd.2012.02.004. [PubMed] [CrossRef] [Google Scholar]

Kahm K., Laxy M., Schneider U., Rogowski W.H., Lhachimi S.K., Holle R. Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care. 2018;41:971–978. doi: 10.2337/dc17-1763. [PubMed] [CrossRef] [Google Scholar]

Prasad R.B., Groop L. Precision medicine in type 2 diabetes. J. Intern Med. 2019;285:40–48. doi: 10.1111/joim.12859. [PubMed] [CrossRef] [Google Scholar]

Ehnert S., Rinderknecht H., Aspera-Werz R.H., Haussling V., Nussler A.K. Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: Challenges of complex models. Arch. Toxicol. 2020;94:3937–3958. doi: 10.1007/s00204-020-02906-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]